BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study
- Vavalà, Tiziana
- Follador, Alessandro
- Tiseo, Marcello
- Galetta, Domenico
- Morabito, Alessandro
- Di Maio, Massimo
- Martelli, Olga
- Caffo, Orazio
- Piovano, Pier Luigi
- Cortinovis, Diego
- Zilembo, Nicoletta
- Casartelli, Clelia
- Banna, Giuseppe Luigi
- Ardizzoia, Antonio
- Barzelloni, Maria Luisa
- Bearz, Alessandra
- Genestreti, Giovenzio
- Mucciarini, Claudia
- Filipazzi, Virginio
- Menis, Jessica
- Rizzo, Elisa
- Barbieri, Fausto
- Rijavec, Erika
- Cecere, Fabiana
- Spitaleri, Gianluca
- Rossi, Antonio
- Novello, Silvia
- Bria, Emilio
DOIAbstract
Non-small-cell-lung-cancer (NSCLC) patients harbouring epidermal growth factor receptor (EGFR) mutations develop drug resistance after 9-12 months of EGFR tyrosine kinase inhibitors (TKIs) therapy pointing out the issue of the second-line treatment choice
Add to ORKG